Cargando…
The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China
BACKGROUND: pT1b esophageal squamous cell carcinoma (ESCC) patients treated by endoscopic resection (ER) required additional treatment with surgical resection (SR) or chemoradiotherapy (CRT) according to 2020 Japan Gastroenterological Endoscopy Society (JGES) guideline. Given the evidences for this...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944708/ https://www.ncbi.nlm.nih.gov/pubmed/36008639 http://dx.doi.org/10.1007/s00464-022-09459-5 |
_version_ | 1784891973920882688 |
---|---|
author | Xue, Xuemin Sun, Qi Jiang, Dongxian Wang, Xinran Liu, Yong Guo, Changyuan Liu, Linxiu Cheng, Na Wang, Guiqi Liu, Yueping Hou, Yingyong Fan, Xiangshan Xue, Liyan |
author_facet | Xue, Xuemin Sun, Qi Jiang, Dongxian Wang, Xinran Liu, Yong Guo, Changyuan Liu, Linxiu Cheng, Na Wang, Guiqi Liu, Yueping Hou, Yingyong Fan, Xiangshan Xue, Liyan |
author_sort | Xue, Xuemin |
collection | PubMed |
description | BACKGROUND: pT1b esophageal squamous cell carcinoma (ESCC) patients treated by endoscopic resection (ER) required additional treatment with surgical resection (SR) or chemoradiotherapy (CRT) according to 2020 Japan Gastroenterological Endoscopy Society (JGES) guideline. Given the evidences for this recommendation were largely based on small-size studies, our study collected 166 cases of ER-treated pT1b patients in order to investigate the efficacy of additional SR as compared to ER-alone treatment. METHODS: A multi-institutional retrospective study in China was conducted. The pT1b ESCC treated by ER + SR (n = 42) and ER-alone (n = 124) from 2007 to 2018 were recruited. Meanwhile, patients with positive lymphovascular invasion (LVI(+)) and/or with positive vertical margin (VM(+)) were put into high-risk group, and those with both VM(−) and LVI(−) were selected into low-risk group. The clinicopathological parameters, lymph node metastasis (LNM), and survival between ER + SR and ER-alone groups were analyzed. RESULTS: In high-risk group, concurrent LNM revealed in surgically resected specimens accounted for 52.6% cases in ER + SR group. After surgical removal, the incidence of post-resection LNM dropped down to 5.6%. However, in low-risk group, patients with ER + SR treatment did not exhibit any concurrent LNM in surgically resected specimens, and the incidence of their overall LNM was similar to that in ER-alone group (0% vs. 2.8%, p = 1.000). More importantly, these cases demonstrated significantly shorter overall survival (OS) than that in ER-alone group (81.8% and 100.0%, respectively, at 3 years; log-Rank: P = 0.010). CONCLUSIONS: For ER-treated pT1b patients in high-risk group, additional SR is strongly recommended. However, for those in low-risk group, additional SR does not generate much benefit for clearance of LNM, but brings harm to shorten their OS. Therefore, additional SR is not recommended for ER-treated pT1b patient in low-risk group. |
format | Online Article Text |
id | pubmed-9944708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-99447082023-02-23 The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China Xue, Xuemin Sun, Qi Jiang, Dongxian Wang, Xinran Liu, Yong Guo, Changyuan Liu, Linxiu Cheng, Na Wang, Guiqi Liu, Yueping Hou, Yingyong Fan, Xiangshan Xue, Liyan Surg Endosc Original Article BACKGROUND: pT1b esophageal squamous cell carcinoma (ESCC) patients treated by endoscopic resection (ER) required additional treatment with surgical resection (SR) or chemoradiotherapy (CRT) according to 2020 Japan Gastroenterological Endoscopy Society (JGES) guideline. Given the evidences for this recommendation were largely based on small-size studies, our study collected 166 cases of ER-treated pT1b patients in order to investigate the efficacy of additional SR as compared to ER-alone treatment. METHODS: A multi-institutional retrospective study in China was conducted. The pT1b ESCC treated by ER + SR (n = 42) and ER-alone (n = 124) from 2007 to 2018 were recruited. Meanwhile, patients with positive lymphovascular invasion (LVI(+)) and/or with positive vertical margin (VM(+)) were put into high-risk group, and those with both VM(−) and LVI(−) were selected into low-risk group. The clinicopathological parameters, lymph node metastasis (LNM), and survival between ER + SR and ER-alone groups were analyzed. RESULTS: In high-risk group, concurrent LNM revealed in surgically resected specimens accounted for 52.6% cases in ER + SR group. After surgical removal, the incidence of post-resection LNM dropped down to 5.6%. However, in low-risk group, patients with ER + SR treatment did not exhibit any concurrent LNM in surgically resected specimens, and the incidence of their overall LNM was similar to that in ER-alone group (0% vs. 2.8%, p = 1.000). More importantly, these cases demonstrated significantly shorter overall survival (OS) than that in ER-alone group (81.8% and 100.0%, respectively, at 3 years; log-Rank: P = 0.010). CONCLUSIONS: For ER-treated pT1b patients in high-risk group, additional SR is strongly recommended. However, for those in low-risk group, additional SR does not generate much benefit for clearance of LNM, but brings harm to shorten their OS. Therefore, additional SR is not recommended for ER-treated pT1b patient in low-risk group. Springer US 2022-08-25 2023 /pmc/articles/PMC9944708/ /pubmed/36008639 http://dx.doi.org/10.1007/s00464-022-09459-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Xue, Xuemin Sun, Qi Jiang, Dongxian Wang, Xinran Liu, Yong Guo, Changyuan Liu, Linxiu Cheng, Na Wang, Guiqi Liu, Yueping Hou, Yingyong Fan, Xiangshan Xue, Liyan The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title | The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title_full | The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title_fullStr | The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title_full_unstemmed | The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title_short | The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China |
title_sort | efficacy of additional surgical resection after endoscopic resection in pt1b esophageal squamous cell carcinoma: a multi-institutional retrospective study in china |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944708/ https://www.ncbi.nlm.nih.gov/pubmed/36008639 http://dx.doi.org/10.1007/s00464-022-09459-5 |
work_keys_str_mv | AT xuexuemin theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT sunqi theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT jiangdongxian theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT wangxinran theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liuyong theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT guochangyuan theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liulinxiu theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT chengna theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT wangguiqi theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liuyueping theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT houyingyong theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT fanxiangshan theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT xueliyan theefficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT xuexuemin efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT sunqi efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT jiangdongxian efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT wangxinran efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liuyong efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT guochangyuan efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liulinxiu efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT chengna efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT wangguiqi efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT liuyueping efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT houyingyong efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT fanxiangshan efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina AT xueliyan efficacyofadditionalsurgicalresectionafterendoscopicresectioninpt1besophagealsquamouscellcarcinomaamultiinstitutionalretrospectivestudyinchina |